[{"id":"919ec320-bb3b-4c51-ae6c-4c43a3a1243b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03596372","created_at":"2021-01-18T17:40:59.249Z","updated_at":"2025-02-25T17:10:28.361Z","phase":"Phase 1","brief_title":"Study of BAY1834942 in Patients With Solid Tumors","source_id_and_acronym":"NCT03596372","lead_sponsor":"Bayer","biomarkers":" CEACAM5 • IL2 • CEACAM6","pipe":"","alterations":" ","tags":["CEACAM5 • IL2 • CEACAM6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinurilimab (BAY1834942)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 02/22/2021","study_completion_date":" 02/22/2021","last_update_posted":"2022-06-02"}]